Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis

Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis

(2018) Tomi O. Sarkanen et al.   SLEEP MEDICINE REVIEWS

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

(2018) Aurelio Cruz-Valdez et al.   Human Vaccines & Immunotherapeutics

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

(2018) Timo Vesikari et al.   Lancet Respiratory Medicine

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

(2018) Daniel Weibel et al.   VACCINE

Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal

(2018) Aldiouma Diallo et al.   VACCINE

Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis

(2018) Yu-Ju Lin et al.   Scientific Reports

Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis

(2017) Alexander Domnich et al.   VACCINE

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

(2017) Beverley J Shea et al.   BMJ-British Medical Journal

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

(2017) Beverley J Shea et al.   BMJ-British Medical Journal

AS03- and MF59-Adjuvanted Influenza Vaccines in Children

(2017) Amanda L. Wilkins et al.   Frontiers in Immunology

State-Level Lifetime Medical and Work-Loss Costs of Fatal Injuries — United States, 2014

(2017) Feijun Luo et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Trends in Childhood Influenza Vaccination Coverage—U.S., 2004–2012

(2017) Tammy A. Santibanez et al.   PUBLIC HEALTH REPORTS

Trends in compliance with two-dose influenza vaccine recommendations in children aged 6 months through 8 years, 2010–2015

(2016) Xia Lin et al.   VACCINE

A review of the changes to the licensing of influenza vaccines in Europe

(2015) Leonoor Wijnans et al.   Influenza and Other Respiratory Viruses

Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age

(2015) Luisanna Zedda et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2

(2015) Syed Sohail Ahmed et al.   Science Translational Medicine

Incidence of narcolepsy before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South Korean soldiers

(2015) Woo Jung Kim et al.   VACCINE

Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

(2015) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data

(2014) T Harris et al.   Eurosurveillance

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial

(2014) Terry Nolan et al.   JOURNAL OF INFECTIOUS DISEASES

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec

(2014) Jacques Montplaisir et al.   PLoS One

Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

(2014) Outi Vaarala et al.   PLoS One

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

(2014) Terry Nolan et al.   VACCINE

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

(2014) Adib Rodriguez Solares et al.   Journal of Infection in Developing Countries

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

(2013) Christopher B Fox et al.   Expert Review of Vaccines

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

(2013) Janet E McElhaney et al.   LANCET INFECTIOUS DISEASES

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

(2013) Charlotte I S Barker et al.   LANCET INFECTIOUS DISEASES

A Population-Based Study of Neurologic Manifestations of Severe Influenza A(H1N1)pdm09 in California

(2012) C. A. Glaser et al.   CLINICAL INFECTIOUS DISEASES

The history of MF59®adjuvant: a phoenix that arose from the ashes

(2012) Derek T O’Hagan et al.   Expert Review of Vaccines

More on Influenza Vaccine in Young Children

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children

(2012) Stan L. Block et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to ,9 Years of Age

(2012) Cynthia Nassim et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to

(2012) Joanne M. Langley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Adjuvanted influenza vaccines

(2012) Nicola Principi et al.   Human Vaccines & Immunotherapeutics

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china

(2011) Fang Han et al.   ANNALS OF NEUROLOGY

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age

(2011) Adriano Arguedas et al.   Human vaccines & immunotherapeutics

Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children

(2011) Timo Vesikari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata

(2011) Danuta M. Skowronski et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study

(2011) Giovanni Della Cioppa et al.   VACCINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE